Camlin Fine Sciences · NSE: CAMLINFINE · BSE: 532834

Q2 FY22 results · Jul–Sep 2021

Camlin Fine Sciences reported revenue from operations of ₹311.22 crore (up 21.2% from Q2 FY21) and net loss of ₹3.88 crore for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.

Consolidated · ₹ crore
Item	Q2 FY22	Q2 FY21	YoY	Q1 FY22	QoQ
Revenue from operations	311.22	256.81	+21.2%	330.83	−5.9%
Other income	0.62	1.28	−51.7%	10.55	−94.1%
Total income	311.84	258.09	+20.8%	341.38	−8.7%
Profit before share of associates & JVs and tax	0.91	17.17	−94.7%	32.57	−97.2%
Share of profit/(loss) of associates & JVs	(0.15)	0.00		(0.02)
Net profit for the period	(3.88)	9.66	Turned loss	23.78	Turned loss
Attributable to shareholders of the company	(5.53)	5.89	Turned loss	22.36	Turned loss
EPS, basic (₹)	(0.43)	0.49	Turned loss	1.75	Turned loss
Net margin (%)	-1.2	3.8		7.2

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q2 FY22	Q2 FY21	YoY	Q1 FY22	QoQ
Revenue from operations	138.17	146.78	−5.9%	145.73	−5.2%
Other income	1.01	1.33	−23.9%	3.83	−73.7%
Total income	139.17	148.10	−6.0%	149.56	−6.9%
Profit before tax	(10.15)	(0.88)	Loss widened	6.97	Turned loss
Net profit for the period	(6.99)	(1.02)	Loss widened	4.73	Turned loss
EPS, basic (₹)	(0.55)	(0.08)	Loss widened	0.37	Turned loss
Net margin (%)	-5.1	-0.7		3.2

Consolidated

Filed with BSE: 13 Nov 2021, 16:39 IST
Board meeting: 12 Nov 2021
Period: 01 Jul 2021 to 30 Sep 2021
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 13 Nov 2021, 16:39 IST
Board meeting: 12 Nov 2021
Period: 01 Jul 2021 to 30 Sep 2021
Review status: Unaudited
Source: XBRL filing on BSE